Semaglutide Improves PMOS Fertility

Researchers at the University of Colorado Anschutz have published a proof-of-concept study in the journal Fertility and Sterility, demonstrating that injectable Semaglutide may offer significant reproductive benefits for women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS). The study, led by Melanie Cree, found that Semaglutide improved reproductive outcomes while also addressing obesity and metabolic dysfunction in participants of the ongoing RESTORE clinical trial. This is particularly important as existing therapies often fail to simultaneously treat both reproductive and metabolic complications of PMOS. The preliminary findings, which emerged earlier than expected, suggest that Semaglutide could become a promising therapeutic option for women seeking improvements in both metabolic and reproductive health, especially those achieving at least 10% body weight loss.